Repository logo
 

Treatment of severe covid-19 with interleukin 6 receptor inhibition.

Published version
Peer-reviewed

Type

Other

Change log

Authors

Rajasundaram, Skanda 

Abstract

The use of tocilizumab or sarilumab in combination with corticosteroids has been an important development in the treatment of severe covid-19. In contrast to monoclonal antibody treatments that target circulating interleukin 6, tocilizumab and sarilumab specifically block the binding of interleukin 6 to its receptor.1 The National Institute for Health and Care Excellence first issued guidance on using these treatments for covid-19 in April 2021, following the release of data from the RECOVERY2 and REMAP-CAP3 trials.

Description

Keywords

Is Part Of

Publisher

BMJ
Sponsorship
Medical Research Council (MC_UU_00002/7)